Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen

Vera Therapeutics, Inc.

New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.
Prior $200M ATM agreement with TD Cowen terminated effective August 5, 2025.
TD Cowen will receive up to 3.0% commission on gross proceeds of shares sold.
Company not obligated to sell any shares; sales subject to company instructions and market conditions.
Issuance will be made under existing S-3 shelf registration statement.

item 1.01item 1.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.